chromium has been researched along with Carcinoma, Transitional Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stamatiou, K | 1 |
| Eto, M; Harada, M; Ichikura, H; Naito, S; Takayama, K; Tatsugami, K; Tokuda, N; Ueno, H | 1 |
2 other study(ies) available for chromium and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
[Hexavalent chromium and bladder cancer risk].
Topics: Animals; Carcinogens, Environmental; Carcinoma, Transitional Cell; Chromium; Cocarcinogenesis; Drinking Water; Greece; Humans; Neoplasm Recurrence, Local; Prevalence; Prospective Studies; Risk; Risk Factors; Urinary Bladder Neoplasms; Water Pollutants, Chemical | 2012 |
In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Topics: Adenoviridae; Animals; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chromium; Gene Transfer Techniques; Genetic Therapy; Humans; Immunoglobulin Fc Fragments; Injections, Intramuscular; Injections, Subcutaneous; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Spleen; Survival Rate; T-Lymphocytes, Cytotoxic; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |